Abstract
Sjögren’s syndrome is an autoimmune disorder primarily affecting women, with decreased saliva and tear production as the principal characteristic. Cognitive, neurological, and psychiatric disorders also are associated with Sjögren’s. The present study addressed the hypothesis that patients with Sjögren’s syndrome differ significantly from matched controls in the prevalence and impact of a number of neuropsychiatric abnormalities. Sjögren’s patients and controls (n = 37 per group) underwent medical and psychiatric evaluation, demographic assessments, quality of life and symptom evaluation, and extensive testing of cognitive function and memory. Patients and controls were closely matched for age, gender distribution, verbal IQ, marital status, educational level, employment status, and current/past medical or psychiatric history. On most subjective self-ratings, Sjögren’s patients reported greater fatigue, impaired physical functioning, feeling depressed, and autonomic symptomatology compared to controls. Impaired memory was described mainly as loss of thought continuity in the midst of a task or activity. However, the majority of objective measures of cognition, psychomotor function, and memory showed minimal differences between groups. Sjögren’s patients rate themselves as impaired on multiple ratings of emotional, cognitive, and physical function, but objective measures of cognition reveal fewer substantive differences between patients and matched controls. Sjögren’s patients perceive deteriorated physical function over time, but they achieve a level of functioning comparable to controls despite the burden of their illness.
Similar content being viewed by others
References
Anaya JM, Talal N (1999) Sjögren’s syndrome comes of age. Semin Arthritis Rheum 28:35–39
Bayetto K, Logan RM (2010) Sjögren’s syndrome: a review of aetiology, pathogenesis, diagnosis and management. Aust Dent J 55(1Suppl):39–47
Fox RI (2005) Sjögren’s Syndrome. Lancet 366:321–331
Kassan SS, Moutsopoulos HM (2004) Clinical manifestations and early diagnosis of Sjögren’s syndrome. Arch Intern Med 164:1275–1284
Cermak JM, Papas AS, Sullivan RM, Dana MR, Sullivan DA (2003) Nutrient intake in women with primary and secondary Sjögren’s syndrome. Eur J Clin Nutr 57:328–334
Cummins MJ, Papas A, Kammer GM, Fox PC (2003) Treatment of primary Sjögren’s syndrome with low-dose human interferon alfa administered by the oromucosal route: combined phase III results. Arthritis Rheum 49:585–593
Fox PC, Bowman SJ, Segal B et al (2008) Oral involvement in primary Sjögren syndrome. J Am ENT Assoc 139:1592–1601
Papas AS, Fernancez MM, Castano RA, Gallagher SC, Trivedi M, Shrotriya RC (1998) Oral pilocarpine for symptomatic relief of dry mouth and dry eyes in patient with Sjögren’s syndrome. Adv Exp Med Biol 438:973–978
Ramos-Casals M, Tzioufas AG, Stone JH, Sisó A, Bosch X (2010) Treatment of primary Sjögren Syndrome: a systematic review. JAMA 304:452–460
Barendregt PJ, Visser MRM, Smets EMA, Tulen JHM, van den Meiracker AH, Boomsma F, Markusse HM (1998) Fatigue in primary Sjögren’s syndrome. Ann Rheum Dis 57:291–295
Strombeck B, Ekdahl C, Manthorpe R, Wikstrom I, Jacobsson L (2000) Health-related quality of life in primary Sjögren’s syndrome, rheumatoid arthritis and fibromyalgia compared to normal population data using SF-36. Scand J Rheumatol 29:20–28
Ng WF, Bowman SJ (2010) Primary Sjögren’s syndrome: too dry and too tired. Rheumatology 49:844–853
Haldorsen K, Bjelland I, Bolstad AI, Jonsson R, Brun JG (2011) A five-year prospective study of fatigue in primary Sjögren’s syndrome. Arthritis Res Ther 13:R167
Godaert GLR, Hartkamp A, Geenen R, Garssen A, Kruize AA, Bijlsma JMR, Derksen RHWM (2002) Fatigue in daily life in patients with primary Sjögren’s syndrome and systemic lupus erythematosus. Ann NY Acad Sci 966:320–326
Valtysdottir ST, Gudbjornsson B, Lindqvist U, Hallgren R, Hetta J (2000) Anxiety and depression in patients with primary Sjögren’s syndrome. J Rheum 27:165–169
Valtysdottir ST, Gudbjornsson B, Hallgren R, Hetta J (2000) Psychological well-being in patients with primary Sjögren’s syndrome. Clin Exp Rheumatol 18:597–600
Delalande S, de Seze J, Fauchais A-L et al (2004) Neurologic manifestations in primary Sjögren syndrome: a study of 82 patients. Medicine 83:280–291
Govoni M, Padovan M, Rizzo N, Trotta F (2001) CNS involvement in primary Sjögren’s syndrome: prevalence, clinical aspects, diagnostic assessment and therapeutic approach. CNS Drugs 15:597–607
Mauch E, Voelk C, Kratzsch G, Krapf H et al (1994) Neurological and neuropsychiatric dysfunction in primary Sjögren’s syndrome. Acta Neurol Scand 89:31–35
Alexander EL (1991) Central nervous system disease in Sjögren’s syndrome. New insights into immunopathogenesis. Rheum Dis clin North Am 18:637–672
DeBattista C, Doghramji K, Menza MA, Rosenthal MH, Fieve RR (2003) Modafinil in Depression Study Group. Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind, placebo-controlled study. J Clin Psychiatry 64:1057–1064
Dinges DF, Weaver TE (2003) Effects of modafinil on sustained attention performance and quality of life in OSA patients with residual sleepiness while being treated with nCPAP. Sleep Med 4:393–402
Johnstone B, Pepmueller PH, Vieth AZ, Komatireddy G (1996) Effective treatment of neuropsychological deficits in Sjögren’s syndrome. Appl Neuropsychol 3:122–127
Le Guern V, Belin C, Henegar C et al (2010) Cognitive function and 99mTc-ECD brain SPECT are significantly correlated in patients with primary Sjögren syndrome: a case–control study. Ann Rheum Dis 69:132–137
Cox PD, Hales RE (1999) CNS Sjögren’s syndrome: an under-recognized and underappreciated neuropsychiatric disorder. J Neuropsych Clin Neurosci 11:241–247
Wyszynski AA, Wyszynski B (1993) Treatment of depression with fluoxetine in corticosteroid-dependent central nervous system Sjögren’s syndrome. Psychosomatics: J Consult Liaison Psychiatry 34:173–177
Shiboski SC, Shiboski CH, Criswell L, Baer A, Challacombe S, Lanfranchi H, Schiødt M, Umehara H, Vivino F, Zhao Y, Dong Y, Greenspan D, Heidenreich AM, Helin P, Kirkham B, Kitagawa K, Larkin G, Li M, Lietman T, Lindegaard J, McNamara N, Sack K, Shirlaw P, Sugai S, Vollenweider C, Whitcher J, Wu A, Zhang S, Zhang W, Greenspan J, Daniels T (2012) Sjögren’s International Collaborative Clinical Alliance (SICCA) Research Groups. Arthritis Care Res 64:475–487
Greenblatt DJ, Harmatz JS, Shapiro L, Engelhardt N, Gouthro TA, Shader RI (1991) Sensitivity to triazolam in the elderly. N Engl J Med 324:1691–1698
Kaplan GB, Greenblatt DJ, Ehrenberg BL, Goddard JE, Cotreau MM, Harmatz JS, Shader RI (1997) Dose dependent pharmacokinetics and psychomotor effects of caffeine in humans. J Clin Pharmacol 37:693–703
Scavone JM, Greenblatt DJ, Harmatz JS, Engelhardt N, Shader RI (1998) Pharmacokinetics and pharmacodynamics of diphenhydramine 25 mg in young and elderly volunteers. J Clin Pharmacol 38:603–609
Spitzer RL, Williams JB, Gibbon M, First MB (1992) The structured clinical interview for DSM-III-R (SCID). I: History, rationale, and description. Arch Gen Psychiatry 49:624–629
Spitzer RL, Williams JBW, Gibbon M, First MB. Structured clinical interview for DSM-III-R, patient edition/non-patient edition, (SCID-P/SCID-NP), Washington, D.C.: American Psychiatric Press, Inc., 1990
Small GW (2002) The Memory Bible: an innovative strategy for keeping the brain young. Penguin, London
Holmes TH, Rahe RH (1967) Holmes-Rahe social readjustment rating scale. J Psychosom Res 11:213–218
Hollingshead AB (1975) Four factor index of social status. Yale University, New Haven
Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD (1989) The fatigue severity scale: application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 46:1121–1123
Ware JEJ, Snow KK, Kosinski M, Gandek B (1993) SF-36 Health survey: manual and interpretation guide. The Health Institute, New England Medical Center
Radloff LS, Teri L (1986) Use of the center for epidemiological studies—depression scale with older adults. Clin Gerontol 5:119–136
Greenblatt DJ, Harmatz JS, Engelhardt N, Shader RI (1989) Pharmacokinetic determinants of dynamic differences among three benzodiazepine hypnotics: flurazepam, temazepam, and triazolam. Arch Gen Psychiatry 46:326–332
Greeenblatt DJ, Harmatz J, Dorsey C, Shader RI (1988) Comparative single-dose kinetics and dynamics of lorazepam, alprazolam, prazepam, and placebo. Clin Pharmacol Ther 44:326–334
Curtis-Prior PB (1996) Computerized methods of neuropsychological assessment. Br J Hosp Med 56:445–449
Sahakian BJ, Owen AM (1992) Computerized assessment in neuropsychiatry using CANTAB. J R Soc Med 85:399–402
Fray PJ, Robbins TW (1996) CANTAB battery: proposed utility in neurotoxicology. Neurotoxicol Teratol 18:499–504
Bright P, Jaldow E, Kopelman MD (2002) The National Adult Reading Test as a measure of premorbid intelligence: a comparison with estimates derived from demographic variables. J Int Neuropsychol Soc 8:847–854
Gladsjo JA, Heaton RK, Palmer BW, Taylor MJ, Jeste DV (1999) Use of oral reading to estimate premorbid intellectual and neuropsychological functioning. J Int Neuro Psychol Soc 5:247–254
Birnbaum J (2010) Peripheral nervous system manifestations of Sjögren’s syndrome: clinical patterns, diagnostic paradigms, etiopathogenesis, and therapeutic strategies. Neurologist 16:287–297
Segal BM, Pogatchnik B, Holker E, Liu H, Sloan J, Rhodus N, Moser KL (2012) Primary Sjögren's syndrome: cognitive symptoms, mood, and cognitive performance. Acta Neurol Scand 125:272–278
Segal B, Bowman SJ, Fox PC et al (2009) Primary Sjögren’s syndrome: health experiences and predictors of health quality among patients in the United States. Health Qual Life Outcomes 7:46
Acknowledgments
This work was supported by a grant from the Sjögren’s Syndrome Foundation.
Disclosures
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Epstein, L.C., Masse, G., Harmatz, J.S. et al. Characterization of cognitive dysfunction in Sjögren’s syndrome patients. Clin Rheumatol 33, 511–521 (2014). https://doi.org/10.1007/s10067-013-2453-6
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-013-2453-6